(Q38012205)

27 August 2017

Thiazolidinedione safety (English)

1 reference

27 August 2017

Jacqueline Kung

1

1 reference

PubMed ID

22616948

27 August 2017

Robert R Henry

series ordinal

2

1 reference

PubMed ID

22616948

27 August 2017

language of work or name

English

0 references

publication date

22 May 2012

1 reference

Expert Opinion on Drug Safety

27 August 2017

1 reference

27 August 2017

11

1 reference

27 August 2017

4

1 reference

27 August 2017

565-579

1 reference

Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Selective modulation of promoter recruitment and transcriptional activity of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Association between serious ischemic cardiac outcomes and medications used to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

A randomized trial of therapies for type 2 diabetes and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Revisiting the rosiglitazone story--lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Fracture risk is a class effect of glitazones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Diabetes drug pioglitazone (Actos): risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Case series of liver failure associated with rosiglitazone and pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Diabetic macular edema associated with glitazone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Glitazone use associated with diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Placental transfer of rosiglitazone in the first trimester of human pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of rifampicin on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of gemfibrozil on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Benzoyl 2-methyl indoles as selective PPARgamma modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Obesity: New life for antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Evolution of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2012.691963

10.1517/14740338.2012.691963

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22616948